Want to see HK:2235 full AI Analyst Report?
Top Page
MicroTech Medical (Hangzhou) Co., Ltd. Class H
(2235)
Select Model
Select Model
Rating:58Neutral
Price Target:
HK$7.50
▲(5.63% Upside)
Action:Reiterated
Date:08/07/26
The score is driven primarily by strong financial fundamentals on growth and balance-sheet conservatism, including a return to positive net income. These positives are tempered by still-developing cash flow (negative free cash flow) and weak technical momentum, while the high P/E valuation reduces upside-adjusted attractiveness.
Positive Factors
Accelerating revenue growth
Sustained +101% revenue growth in 2025 indicates durable product adoption and expanding market penetration in diabetes devices. Growth supports scale economies, enlarges the recurring consumables base, and provides room to invest in distribution and R&D over the next 2–6 months and beyond.
Negative Factors
Negative free cash flow
Persistently negative free cash flow (-6.1M in 2025) implies ongoing capital intensity or working-capital strain despite revenue growth. That limits self-funded expansion, may require external financing, and constrains durability of returns until FCF turns sustainably positive.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating revenue growth
Sustained +101% revenue growth in 2025 indicates durable product adoption and expanding market penetration in diabetes devices. Growth supports scale economies, enlarges the recurring consumables base, and provides room to invest in distribution and R&D over the next 2–6 months and beyond.
Read all positive factors
MicroTech Medical (Hangzhou) Co., Ltd. Class H (2235) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.82B
Dividend YieldN/A
Average Volume (3M)94.87K
Price to Earnings (P/E)27.9
Beta (1Y)0.34
Revenue Growth94.80%
EPS GrowthN/A
CountryHK
Employees702
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.11
Shares Outstanding169,175,840
10 Day Avg. Volume262,670
30 Day Avg. Volume94,870
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)1.42
Price to Sales (P/S)4.33
P/FCF Ratio-468.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.21
Revenue Forecast (FY)HK$908.01M
MicroTech Medical (Hangzhou) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
MicroTech Medical (Hangzhou) Co., Ltd. focuses on the innovation, production, and market distribution of essential medical devices and consumables for diabetes management. Its operations extend across the People's Republic of China and into global...
How the Company Makes Money
The company makes money primarily by selling diabetes management medical devices and the recurring consumables required to use them. Key revenue streams typically include: (1) sales of insulin pump systems (the durable device component), which may...
MicroTech Medical (Hangzhou) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
84
Very Positive
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 660.79M | 345.62M | 248.35M | 173.54M | 151.40M |
| Gross Profit | 357.42M | 182.85M | 123.22M | 79.66M | 70.88M |
| EBITDA | 29.02M | -121.38M | -184.12M | -110.19M | -39.80M |
| Net Income | 40.15M | -63.12M | -125.02M | -35.04M | -48.18M |
Balance Sheet | |||||
| Total Assets | 2.31B | 2.15B | 2.16B | 2.29B | 2.33B |
| Cash, Cash Equivalents and Short-Term Investments | 1.55B | 1.71B | 1.89B | 2.05B | 2.15B |
| Total Debt | 91.37M | 4.20M | 5.06M | 717.00K | 255.00K |
| Total Liabilities | 287.07M | 171.72M | 97.70M | 82.06M | 82.48M |
| Stockholders Equity | 2.02B | 1.97B | 2.06B | 2.21B | 2.25B |
Cash Flow | |||||
| Free Cash Flow | -6.11M | -203.88M | -181.69M | -137.45M | -62.94M |
| Operating Cash Flow | 31.80M | -120.65M | -153.00M | -107.67M | -44.22M |
| Investing Cash Flow | -351.63M | 121.16M | -540.70M | -965.58M | 97.69M |
| Financing Cash Flow | 55.22M | -33.15M | -23.46M | -20.57M | 1.57B |
MicroTech Medical (Hangzhou) Co., Ltd. Class H Technical Analysis
Negative
7.10
Price Trends
7.11
Negative
7.37
Negative
7.34
Negative
Market Momentum
-0.05
Positive
36.61
Neutral
6.84
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2235, the sentiment is Negative. The current price of 7.1 is below the 20-day moving average (MA) of 7.12, below the 50-day MA of 7.11, and below the 200-day MA of 7.34, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 36.61 is Neutral, neither overbought nor oversold. The STOCH value of 6.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2235.
MicroTech Medical (Hangzhou) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$448.87M | 4.47 | 13.95% | 6.92% | 10.95% | 9.26% | |
59 Neutral | HK$5.96B | 91.93 | 1.72% | ― | 0.75% | -20.22% | |
58 Neutral | HK$2.82B | 27.86 | 4.06% | ― | 94.80% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$3.43B | -20.49 | -7.65% | ― | 21.23% | 36.89% | |
43 Neutral | HK$1.63B | -0.86 | -6.69% | ― | ― | ― | |
40 Underperform | HK$11.65B | 31.24 | 6.07% | 0.06% | -3.62% | ― |
* Healthcare Sector Average
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
6.68
-2.12
-24.09%
HK:0853
MicroPort Scientific
6.08
-7.83
-56.29%
HK:9996
Peijia Medical Ltd.
5.06
-2.65
-34.37%
HK:1302
LifeTech Scientific Corporation
1.38
-0.57
-29.12%
HK:1612
Vincent Medical Holdings Limited
0.67
-0.38
-36.36%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.28
-6.07
-82.59%
MicroTech Medical (Hangzhou) Co., Ltd. Class H Corporate Events
MicroTech Medical Sets August Board Meeting to Review 2026 Interim Results and Possible Dividend
Aug 7, 2026
MicroTech Medical (Hangzhou) Co., Ltd. has scheduled a board meeting for August 21, 2026 to review and approve its unaudited interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consider w...
MicroTech Medical Signals Strong H1 2026 Turnaround on CGM Growth
Jul 30, 2026
MicroTech Medical has issued a positive profit alert for the first half of 2026, projecting revenue of at least RMB400 million, up more than 63% year on year, and a net profit of at least RMB36 million, marking a turnaround from a loss in the same...
MicroTech Medical Wins South Korean Approval for Glucose Monitoring System
Jul 14, 2026
MicroTech Medical announced that its LinX Continuous Glucose Monitoring System has received marketing approval in South Korea for use in adult patients. South Korea is highlighted as a key East Asian market, with high diabetes prevalence, strong r...
MicroTech Medical Shareholders Unanimously Back 2025 Results and Dividend Plan at AGM
Jun 10, 2026
MicroTech Medical (Hangzhou) Co., Ltd. held its 2025 annual general meeting in Hangzhou on June 10, 2026, with shareholders representing about 60.67% of voting rights in attendance. The meeting complied with PRC company law and the firm’s ar...
MicroTech Medical Sets 2025 AGM to Approve Results and Expand Capital Mandates
May 20, 2026
MicroTech Medical (Hangzhou) Co., Ltd. has convened its 2025 annual general meeting for June 10, 2026, in Hangzhou to seek shareholder approval of its 2025 annual report, audited financial statements and key governance reports from the board and s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.